Attovia Therapeutics (ATTO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.8M

Revenue (quarter)

$450,000.00

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$1.8M

Gross margin

100.00%

Net income (trailing twelve months)

−$70.4M

Net income (quarter)

−$20.7M

Net income growth (year over year)

−43.27%

Net margin

−3910.00%

Return on equity

—

EPS (trailing twelve months)

−$17.05

Book value per share

—

P/E (trailing twelve months)

—

Price to book

5.96

Debt to assets

12.14%

Payout ratio

—

Dividend yield

—

Company profile

Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.

• Is Attovia Therapeutics (ATTO) profitable?

  No. Attovia Therapeutics reported a net loss of $70.4M over the trailing twelve months.

• How much revenue does Attovia Therapeutics (ATTO) make?

  Attovia Therapeutics generated $1.8M in revenue over the trailing twelve months.

• How do I buy stock in Attovia Therapeutics (ATTO)?

  ATTO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.